Vertex Pharmaceuticals Inc (VRTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) has a cash flow conversion efficiency ratio of 0.074x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.43 Billion) by net assets ($19.36 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vertex Pharmaceuticals Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Vertex Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vertex Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vertex Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
0.073x |
|
Parker-Hannifin Corporation
NYSE:PH
|
0.067x |
|
HDFC Bank Limited
F:HDFA
|
N/A |
|
Starbucks Corporation
NASDAQ:SBUX
|
-0.043x |
|
DBS GROUP ADR/4 SD 1
F:DEV
|
N/A |
|
ServiceNow Inc
NYSE:NOW
|
0.173x |
|
Cadence Design Systems Inc
NASDAQ:CDNS
|
0.054x |
|
Quanta Services Inc
NYSE:PWR
|
0.043x |
Annual Cash Flow Conversion Efficiency for Vertex Pharmaceuticals Inc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Vertex Pharmaceuticals Inc from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Vertex Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.67 Billion | $3.63 Billion | 0.195x | +748.08% |
| 2024-12-31 | $16.41 Billion | $-492.60 Million | -0.030x | -114.92% |
| 2023-12-31 | $17.58 Billion | $3.54 Billion | 0.201x | -32.22% |
| 2022-12-31 | $13.91 Billion | $4.13 Billion | 0.297x | +13.41% |
| 2021-12-31 | $10.10 Billion | $2.64 Billion | 0.262x | -30.12% |
| 2020-12-31 | $8.69 Billion | $3.25 Billion | 0.375x | +45.23% |
| 2019-12-31 | $6.09 Billion | $1.57 Billion | 0.258x | -9.96% |
| 2018-12-31 | $4.44 Billion | $1.27 Billion | 0.286x | -30.77% |
| 2017-12-31 | $2.04 Billion | $844.94 Million | 0.414x | +134.49% |
| 2016-12-31 | $1.34 Billion | $236.10 Million | 0.176x | +152.76% |
| 2015-12-31 | $1.09 Billion | $-365.43 Million | -0.334x | +28.46% |
| 2014-12-31 | $1.10 Billion | $-513.20 Million | -0.467x | -1129.56% |
| 2013-12-31 | $1.36 Billion | $-51.57 Million | -0.038x | -117.52% |
| 2012-12-31 | $1.23 Billion | $267.84 Million | 0.217x | +45.75% |
| 2011-12-31 | $965.51 Million | $143.74 Million | 0.149x | +111.81% |
| 2010-12-31 | $503.97 Million | $-635.44 Million | -1.261x | -223.29% |
| 2009-12-31 | $1.10 Billion | $-427.59 Million | -0.390x | +58.87% |
| 2008-12-31 | $238.87 Million | $-226.48 Million | -0.948x | -1.88% |
| 2007-12-31 | $271.30 Million | $-252.48 Million | -0.931x | -1994.95% |
| 2006-12-31 | $505.94 Million | $-22.48 Million | -0.044x | +93.82% |
| 2005-12-31 | $239.18 Million | $-172.05 Million | -0.719x | +82.07% |
| 2004-12-31 | $35.44 Million | $-142.16 Million | -4.011x | -361.47% |
| 2003-12-31 | $192.84 Million | $-167.62 Million | -0.869x | -313.72% |
| 2002-12-31 | $378.58 Million | $-79.54 Million | -0.210x | -1136.94% |
| 2001-12-31 | $475.35 Million | $-8.07 Million | -0.017x | +64.72% |
| 2000-12-31 | $345.76 Million | $-16.64 Million | -0.048x | +68.33% |
| 1999-12-31 | $209.19 Million | $-31.80 Million | -0.152x | -20.34% |
| 1998-12-31 | $246.20 Million | $-31.10 Million | -0.126x | -270.90% |
| 1997-12-31 | $276.00 Million | $-9.40 Million | -0.034x | +88.95% |
| 1996-12-31 | $130.80 Million | $-40.30 Million | -0.308x | -64.26% |
| 1995-12-31 | $85.30 Million | $-16.00 Million | -0.188x | -34.62% |
| 1994-12-31 | $105.50 Million | $-14.70 Million | -0.139x | -180.20% |
| 1993-12-31 | $49.50 Million | $8.60 Million | 0.174x | +243.91% |
| 1992-12-31 | $43.90 Million | $-5.30 Million | -0.121x | -152.08% |
| 1991-12-31 | $52.20 Million | $-2.50 Million | -0.048x | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more